FARSA and mantle cell lymphoma: Next, we focused on the MCL and compared the expression levels of FARSA in three MCL cell lines, of which, Jeko cells are sensitive to Bortezomib (BTZ), the first proteasome inhibitor approved for the treatment of relapsed/refractory patients with MCL, whereas REC1 and Mino cells are BTZ-resistant MCL cell lines [12,13].